 |
(Natural News) A drug that treats periodic paralysis may be pricing those afflicted with the condition out of the market. Originally a medicine approved for glaucoma treatment, the U.K. National Health Service made Daranide available for the equivalent of about $500 U.S. dollars for a year’s supply. Daranide reportedly didn’t work well for the eye disease,... |
Drug makeover: When a drug underperforms, Big Pharma renames it, labels it for another use and jacks up the price
Continue Reading
Bagikan Berita Ini
Related Posts :
If the coronavirus is no big deal, why is China engaged in draconian crackdown measures?- No power, no problem: 5 Ways to stay warm when the power is out
- Coronavirus infections explode across Diamond Princess cruise ship, now reaching 61 confirmed cases out of 273 tested (22% infection rate)
- WikiHow says "anti-vaxxer" parents are violent child abusers, urges children to recruit doctors to overrule parental consent as part of Big Tech's war on health freedom and vaccine truth
- America continues to use 100 herbicides and pesticides that are BANNED in other countries
0 Response to "Drug makeover: When a drug underperforms, Big Pharma renames it, labels it for another use and jacks up the price"
Post a Comment